New Report: Companion App Market Set to Grow Tenfold, Reaching $20B Revenue Uplift by 2029
New R2G report. Integrated drug-app-service bundles are reshaping patient support and commercial strategy in pharma. 3,000 companion apps will help Pharma to generate $20B of incremental revenues by 2029. Selecting the right drugs is essential for the success of companion apps.
Research2Guidance has published its latest market report, “The Rise of Companion Apps: A $20B Opportunity for Pharma by 2029,” providing an in-depth analysis of the emerging digital health segment of companion solutions, integrated drug, app, sensor, and service bundles designed to support patients throughout their treatment journey.
A New Class of Pharma-Digital Integration
Companion apps are evolving into strategic tools for pharmaceutical companies. Unlike generic digital health tools, these apps are tightly coupled with specific drugs or groups of therapies and are designed to improve clinical outcomes, patient engagement, and ultimately, drug sales.
While most of today’s companion apps are used during the initiation phase of treatment, a growing number also support early patient identification and onboarding. This expands their value beyond adherence support into the commercial realm, offering pharmaceutical companies a scalable way to increase their brand reach and patient base.
By 2029, the number of companion app solutions is expected to exceed 3,000 globally, though adoption will vary significantly across regions. To succeed in this evolving market, pharmaceutical companies will need to overcome critical barriers related to regulation, reimbursement, integration, and user engagement.
- Low user retention and poor app design undermine long-term engagement.
- Unclear regulatory paths for Software as a Medical Device (SaMD) hinder broader rollout.
- Reimbursement mechanisms are largely undeveloped, limiting scalability.
- Limited integration into healthcare professionals (HCP) workflows reduces clinical utility.
Pharma’s motivation to launch companion apps and navigate market entry barriers will strengthen over time, as the commercial and clinical value of these solutions becomes increasingly clear and competitive pressure intensifies from early adopters:
- Large incremental revenue potential of $20 billion (2029)
- A large addressable market of 1.8 billion (1.1 billion with capable devices) for chronic patients globally as a primary target group,
- Emerging best-practice models from early adopters/competitors, offering replicable playbooks for new entrants.
Drug selection will be key to launching a digital companion solution for a drug.
The report outlines a strategic framework to help pharmaceutical companies assess which drugs in their portfolios or pipelines are most suited for companion app integration. This includes eight strategic benefit criteria covering clinical value, patient population size, disease area digital maturity, and more.
“The Rise of Companion Apps: A $20B Opportunity for Pharma by 2029” is available now. It includes detailed market sizing, adoption forecasts, ROI benchmarks, and strategic guidance for pharma executives, digital health teams, and innovation leads.
